Introduction
============

Both the upper and lower parts of the human digestive tract harbor a complex ecosystem of bacteria, fungi, protozoa, and viruses, referred to as the microbiome. It begins to form even before birth, in the uterus, developing for another 2--3 years after birth to become a stable, fully functioning microbiome, until the physiological changes associated with senescence lead again to substantial shifts in its composition ([@B5]; [@B1]; [@B78]). The lower part of the digestive tract gets "inoculated" every day by about 10^11^ bacteria from the oral cavity and microbial species detected in the oral and fecal microbiota overlap in about 45% of tested individuals ([@B112]; [@B109]). Moreover, via the blood stream, these oral bacteria can disseminate all over the body. Fungal microbiota can colonize the gut perorally as well, with some strains detected in the gut likely to be contaminants from the environment or food, rather than commensals ([@B127]). The composition and function of the microbiome change along the digestive tract, from the oral cavity to the rectum. These differences have been previously described in detail ([@B9]; [@B52]) and will be briefly outlined below.

Collectively, the genes encoded by the microbial genomes outnumber the genes in the human genome about 100-fold and this variation enables the commensal microbiota to use substrates indigestible by humans ([@B101]). Products of microbial metabolic activity include vitamins, short-chain fatty acids (SCFAs), and other compounds important for host cell metabolism and survival. Moreover, the host's physical interaction with or sensing of the microbial components is important for proper mucosal barrier function and mucosal immune system development and homeostasis. On the other hand, recent studies have shown that some commensal microbes can under certain conditions become pathogenic -- so called pathobionts. Mechanisms include expression of virulence factors, such as adhesion molecules or proteases, or formation of a biofilm, and such activity can lead to disease initiation or progression. One such example is *Escherichia coli*, a large and diverse group of various bacterial serotypes. *E. coli* strains differ in their activities and biological roles: some of them are gut commensals and commercially available probiotics, others can be pathogens causing gastrointestinal and urinary infections or pathobionts associated with inflammatory bowel disease (IBD) and colorectal cancer (CRC).

The jury is still out on what triggers this transformation of commensals into pathobionts; it might be that a change in the gut microenvironment simply allows the microbes to interact with the host in an aberrant way. The gut microbiota composition and function can be influenced by various factors (**Figure [1](#F1){ref-type="fig"}**). For instance, many substances produced by the host and secreted into gut lumen, such as antibacterial peptides, secretory IgA, mucins, cytokines, or neuromediators, can shape the microbial community. Their production depends on host gene polymorphisms and their expression in host cells is often driven by microbial stimulation, creating a positive feedback loop. Mechanisms responsible for cancer development include some of these factors but others are still under scientific investigation.

![Factors influencing microbiome composition. Microbiome composition is influenced on several levels by factors from external environment, factors resulting from the interaction of microbiota with the host and mutual interaction of the microbiome components.](fmicb-09-00774-g001){#F1}

Colorectal cancer is the most prevalent type of cancer in developed and developing countries ([@B35]). Only a small percentage of colorectal cancers is hereditary or associated with certain predisposing conditions, such as chronic intestinal inflammation in IBD patients. The majority of cases thus represents sporadic cancers (85--95%) and can be, to some extent, influenced by environmental factors. The composition and metabolic activity of gut microbiota may be therefore a crucial component of CRC pathogenesis ([@B7]).

Findings of significant colonization of cancer tissue by microbes usually found in the oral cavity have sparked a debate about a possible involvement of oral microbiota in CRC development process. Many experimental studies have provided evidence for a significant role of microbiota in carcinogenesis. However, due to the complexity of microbial cooperation and interaction with the host, all the underlying mechanisms are yet to be elucidated. Here, we review the properties of bacterial and fungal populations inhabiting the oral cavity and gut, with emphasis on their association with CRC pathogenesis.

Oral Microbiota
===============

The microorganisms found in the human oral cavity are referred to as the human oral microbiome and play a crucial role in maintenance of homeostasis in the mouth. Each individual's oral microbiome consists of a distinct set of microorganisms. The mouth supports one of the most diverse microbial communities compared with other body sites, such as the skin and vagina, due to its heterogeneity and the interrelationships between the different anatomic structures ([@B133]). The constantly humid environment of the oral cavity is maintained at a relatively stable temperature (34--36°C), while the varying pH levels and different types of diet contribute to the substantial microbiome variability ([@B82]). Habitats of the oral cavity are represented by both hard (teeth) and soft tissues (cheek, tongue, lip, gingival sulcus, attached gingiva, hard and soft palate) and their interface (subgingival and supragingival margins, and gingival crevices around teeth). The contiguous extensions of the oral cavity, including the tonsils, pharynx, esophagus, Eustachian tube, middle ear, trachea, lungs, nasal passages, and sinuses, are also colonized by the oral microbiome but the majority of studies describing the oral microbiome composition include only samples from the oral cavity ([@B79]; [@B2]). Moreover, all these structures are constantly moistened by two physiological fluids, saliva and the gingival crevicular fluid, which help to maintain the oral microbiome homeostasis by providing water, nutrients, antibodies, and antimicrobial and adherence factors ([@B82]).

The National Institute of Health's Human Microbiome Project identified the most dominant phyla that account for over 95% of the entire oral microbiome: *Firmicutes*, with the *Streptococcus* as a dominant genus, *Bacteroidetes*, strongly represented by *Prevotella* and *Proteobacteria*, with highly abundant *Haemophilus*, *Fusobacteria,* and *Actinobacteria* ([@B52]; [@B53]; [@B141]). The oral cavity displays greater alpha-diversity (species richness) than either the skin or vagina, characterized by uniform abundance of the major species ([@B53]). On the other hand, beta-diversity, i.e., differences in microbiome composition in oral sites among various subjects, is the lowest compared to the other body sites ([@B53]). Within the oral cavity, the highest microbiota richness has been found in the gingival plaque and in saliva, whereas the lowest richness has been described in keratinized gingiva ([@B53]; [@B141]). It seems that saliva contributes unevenly to the microbial composition of different sites in the oral cavity. Due to its rapid turnover and low levels of nutrients, saliva itself does not contain a stable indigenous biota and owes its high alpha-diversity primarily to bacteria shed from other oral tissues ([@B79]). In general, species like *Streptococcus, Gemmella, Granulicatella, Veillonella,* and *Fusobacterium* can be detected across almost all oral sites, while others are represented only at one or two oral sites, e.g., *Prevotella, Bacteroides, Corynebacterium, Pasteurella,* and *Neisseria* ([@B53]). Bacterial species in the oral cavity find the most stable environment at the supragingival or subgingival tooth surfaces. These non-shedding surfaces are covered by persisting biofilms composed mainly by *Streptococcus* and *Actinomyces*, representing the earliest colonizers of teeth, and *Veillonella* ([@B113]; [@B120]). Taken together, although most microbial species found in the oral cavity differ in their abundance, their representation and activity is more important.

Oral Microbiome and Oral Diseases
=================================

A considerable number of oral conditions, including caries and periodontal diseases, endodontic infections, alveolar osteitis, and tonsillitis is connected to detrimental alteration in microbiota composition -- a dysbiosis ([@B24]; [@B100]). For instance, periodontal inflammation is directly induced by microbes colonizing the biofilm in the gingival sulcus and, at later stages, in the periodontal pockets. These oral biofilms contain 100s of different bacterial species in one periodontal lesion, with composition different from that in healthy periodontium ([@B113]; [@B120]). Initially, the plaque forms only supragingivally but if it is not removed properly, after a few days it spreads below the gingival margin and into the sulcus. There, after the depletion of oxygen, a new environment is established, where anaerobic bacteria can flourish. Three most destructive anaerobic bacteria involved in severe periodontal disease, the so called "red complex," include *Treponema denticola*, *Tannerella forsythia* and *Porphyromonas gingivalis* ([@B114]). Aggressive form of periodontitis is further associated with *Aggregatibacter actinomycetemcomitans* ([@B111]). The immunopathological mechanisms in periodontal disease development and course have been recently thoroughly reviewed by [@B45]. Recurrent aphthous stomatitis is also connected to changes in microbiota composition; decreased abundance of *Streptococcus salivarius* and increased *Acinetobacter johnsonii* have been linked to the disease incidence ([@B12]; [@B66]).

As mentioned previously, the human microbiome diversity is not limited only to bacteria but also includes fungal species. However, this oral mycobiome have been only recently characterized and despite its potential great scientific importance, we found only few studies where its composition was analyzed using high throughput sequencing. [@B41] reported that healthy oral mycobiota contained 74 culturable and 11 non-culturable fungal genera. They have revealed great inter-individual variation and proposed that the presence of certain fungal isolates (e.g., *Candida, Aspergillus, Cryptococcus*) probably predisposes the host to opportunistic infections. *Malassezia* species, previously described as commensals and pathogens of the skin and lungs, have been recently found as predominant commensals in saliva ([@B108]; [@B30]). Many other species are likely still waiting to be discovered and were not detected earlier because of their special growth requirements ([@B88]). The first evidence of interactions among members of the oral mycobiome community and their association with specific disease came from a study characterizing the oral mycobiome in HIV patients ([@B87]). The authors found that a decrease in abundance of an indigenous fungus *Pichia* in uninfected individuals went hand in hand with an increase in abundance of *Candida*, suggesting an antagonistic relationship. *Pichia* inhibits *Candida* by different mechanisms, including competition for nutrients and secretion of factors that disrupt the latter's ability to adhere, germinate, and form biofilms. Moreover, they found a negative correlation between *Candida* and *Campylobacter* in HIV-infected subjects, whereas in healthy subjects, no correlation between *Candida* and bacterial species was detected ([@B87]). Recently, [@B96] published a pilot study describing oral mycobiome in healthy subjects and those with periodontal disease. In diseased subjects, they found a slightly increased abundance of *Candida* genera which is in agreement with previous culture-based studies ([@B131]; [@B16]). Despite those first studies aiming for a deeper understanding of the factors affecting the oral mycobiota composition, information about their direct and indirect effects on human health and the interactions between the fungi and bacteria is still lacking.

The involvement of microbiota in the pathogenesis of oral diseases has been documented using gnotobiotic rat and mouse models of human diseases. Germ-free animals can be obtained by delivering the young by sterile Cesarean section and raising them aseptically in isolators for germ-free rearing. Such animals made it possible to study the effects of commensal bacteria in the oral cavity, including the effects on periodontal tissues. In germ-free mice and rats, it was demonstrated that periodontal disease and caries, similarly to other human inflammatory diseases, cannot be experimentally induced in the absence of microbiota ([@B49]; [@B123]). Experimental animal models (e.g., the gavage model of periodontal disease) and *in vitro* studies revealed that certain components of oral microbiota, mainly *P. gingivalis*, play a crucial role in the innate host defense of periodontium and that dysregulation of the immune response in the presence of oral microbiota leads to inflammation and alveolar bone loss ([@B56]; [@B26]; [@B92]). The mechanisms by which microbiota triggers the pathological changes are not yet fully understood, however, new approaches promise to shed light on the role of oral microbiota ([@B67]; [@B97]).

Oral Microbiome and Extra-Oral Diseases
=======================================

Dysbiosis of the oral microbiome is not only connected with the incidence and maintenance of oral diseases, but has been also implicated in the pathogenesis of autoimmune, inflammatory, and neoplastic diseases (e.g., heart disease, respiratory illnesses, psoriasis, psoriatic arthritis, and carcinogenesis at various sites) ([@B48]; [@B104]; [@B31]; [@B130]). Moreover, oral microbiota seems to affect the outcome of pathological pregnancy (preterm birth, abortions, etc.); reviewed by [@B23]. Periodontal bacterial DNA has been found in atherosclerotic plaques of patients suffering from ischemic heart disease and atherosclerosis ([@B39], [@B38]). Bacteria may initiate or exacerbate atherosclerotic processes through activation of innate immunity, direct involvement of mediators activated by dental plaque antigens in atheroma processes, or involvement of cytokines and heat shock proteins from dental plaque bacteria. There might be also genetic predisposing factors influencing both diseases ([@B13]). Furthermore, patients with rheumatoid arthritis have a higher prevalence of periodontal disease and vice versa ([@B62]; [@B44]). Bacterial DNA has been detected in the synovial fluid of patients with rheumatoid arthritis or with failed prosthetic joints, suggesting the possibility of infection translocating from the periodontal tissue to the synovium ([@B121]). The oral microbiome is not confined to spreading to contiguous epithelial surfaces, but can also be carried by the bloodstream to distant body sites, such as the heart, skin, and joints. Oral microbiota enters the bloodstream during routine daily activities like tooth brushing or through inflamed tissue in the course of oral diseases ([@B125]). The mechanisms of dissemination of potentially pathogenic microbes from the oral cavity through bloodstream are still not clear. Potential connection with systemic low-grade inflammation has been also discussed ([@B99]).

In most conditions discussed so far, no particular microbe or microbes have been described as a causative agent. However, thanks to advances in molecular methods, presence of *Fusobacteria* and other oral bacteria has been recently demonstrated in various systemic pathological conditions, including digestive diseases, such as appendicitis, IBD and CRC. Moreover, a correlation of the presence of oral bacteria *P. gingivalis* and *A. actinomycetemcomitans* with an increased risk of developing pancreatic cancer has been observed in a large group of subjects with incident primary pancreatic adenocarcinoma ([@B34]). Several recent studies have repeatedly confirmed the presence of oral bacteria in the gut, especially in association with CRC mucosa. For instance, [@B89] have shown that a substantial part of gut microbiome associated with CRC is composed of oral bacteria and *Fusobacterium* in particular. [@B86] also proposed a role of oral bacteria in CRC development. They conducted a retrospective study in a huge cohort of women and discovered an association of periodontal disease and tooth loss with CRC morbidity and found that women with less than 17 teeth may be at a greater risk of incident CRC ([@B86]).

Oral Microbiota and Colorectal Carcinogenesis
=============================================

It is generally accepted that the gut microbiome plays a role in CRC development. Experimental proof of gut microbiota involvement in CRC development came from gnotobiotic animal models ([@B103]; [@B132]; [@B7]; [@B68]; [@B124]). Recent studies using next generation sequencing and polymerase chain reaction have shown that *Fusobacterium nucleatum* is frequently detected in stool and biopsy samples from CRC patients ([@B19]; [@B70]; [@B36]). These adhesive, anaerobic Gram-negative bacteria attract considerable attention in search for possible mechanisms behind their inflammatory and tumorigenic activity. Some of the features of *F. nucleatum* and the host responses are already known: *F. nucleatum* modulates E-cadherin/β-catenin signaling via its FadA adhesin/invasin -- a key virulence factor, and alters macrophage infiltration and methylation of the CDKN2A promoter in CRC lesions ([@B106]; [@B93]). It seems that Fap2 Gal-GalNAc lectin of *F. nucleatum* could be responsible for its tendency to bind to tumor cells displaying Gal-GalNAc moieties ([@B3]). Moreover, several other virulence proteins that might participate in inflammatory and neoplastic processes have been described in *F. nucleatum,* using proteomic approaches ([@B140]). In the host, *F. nucleatum* activates numerous immune responses including human β-defensin production, lymphocyte apoptosis, and production of proinflammatory cytokines interleukin (IL)-6, IL-8, and TNF-α ([@B47]).

The fact that *Fusobacterium* is highly abundant in patients with CRC led to various efforts to apply this finding for clinical purposes. For instance, a highly sensitive DNA test for *F. nucleatum* has been developed for screening and prognosis of CRC in Japan ([@B138]). *Fusobacterium* has been recently shown to predict the aggressiveness and recurrence of CRC and its resistance to chemotherapy. It seems to be modifying the innate immune signaling and regulating specific microRNAs that activate the autophagy pathway ([@B139]). In connection with this finding, an argument has been made to use anti-*F. nucleatum* therapy together with chemotherapy.

The dietary patterns leading to CRC development have been studied for several decades. Recently, it was shown that individuals consuming a western-type diet have a higher incidence of *Fusobacterium*-associated CRC and that diets rich in whole grains and dietary fiber are associated with a lower risk of *F. nucleatum*-positive CRC ([@B84]).

Despite the clinical observation of increased abundance of *Fusobacterium* in patients with CRC (especially in chemoresistant forms of CRC), direct clinical evidence of a causal relationship is still lacking. A recent study revealed that fusobacterial abundance is not significantly increased in fecal samples of patients with adenomas, implying that the relationship between *Fusobacterium* and CRC might not be causal after all. [@B6] hypothesize that *Fusobacterium* is more likely just a passenger colonizing the favorable niche in a gut with CRC, rather than the driver of cancer development. Experimental evidence of its potential causal role is based on *in vitro* and animal models of CRC. For instance, it has been shown that *F. nucleatum* potentiates tumorigenesis in monoassociated Apc^min/+^ mice ([@B69]).

While *Fusobacterium* is the most studied periodontal microbe in connection to CRC, other components of the oral microbiome may also be implicated in CRC pathogenesis and will be discussed later (**Table [1](#T1){ref-type="table"}**).

###### 

Oral microbiota and its possible mechanisms related to tumorigenesis.

  Microbial genera       Activity                                                                                                                                             Reference
  ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  *Streptococcus*        Adhesion, co-aggregation Biofilm formation Protease activity Hemolytic activity                                                                      [@B25] [@B29] [@B64] [@B136]
  *Peptostreptococcus*   Biofilm formation Antiapoptotic effect Hydrogen sulfide production                                                                                   [@B128] [@B94]
  *Parvimonas*           Biofilm formation Hemolytic activity Proinflammatory stimulation Hydrogen sulfide production                                                         [@B136] [@B81] [@B17]
  *Dialister*            Biofilm formation Proinflammatory stimulation                                                                                                        [@B25] [@B116]
  *Mogibacterium*        Biofilm formation                                                                                                                                    [@B18]
  *Fusobacterium*        Adhesion Proinflammatory stimulation Immune evasion Hemolytic activity Hydrogen sulfide production                                                   [@B69] [@B106] [@B136] [@B22]
  *Porphyromonas*        Biofilm formation Immune evasion Antiapoptotic effect Protease activity Hemolytic activity Hydrogen sulfide production Proinflammatory stimulation   [@B55] [@B80] [@B98] [@B136] [@B94] [@B116]
  *Campylobacter*        Hemolytic activity Proinflammatory stimulation                                                                                                       [@B136] [@B81]
  *Candida*              Adhesion Biofilm formation Protease activity Hemolytic activity                                                                                      [@B29] [@B43]

Gut Microbiome, Metabolic Activity, and Colon Carcinogenesis
============================================================

Thanks to advances in high-throughput sequencing and metabolomic approaches, we have a growing understanding of the composition and metabolic activity of the microbiome associated with colorectal carcinogenesis. Studies have shown that gut microbiome differs between healthy individuals and adenoma/carcinoma patients and that microbial diversity in cancer is reduced ([@B95]). The adenoma-carcinoma sequence in CRC development suggests an associated continuous alteration of the resident microbiome, which is supported by recent research. Analyses of fecal microbiome composition in patients with adenoma have shown increased normalized abundance of genera such as *Actinomyces*, *Corynebacterium*, *Porphyromonas*, *Mogibacterium,* and *Haemophilus* when compared with healthy individuals ([@B95]; [@B46]). Cancer patients have shown further differences in fecal microbiota composition, with a marked enrichment of *Ruminococcus*, *Oscillibacter*, and *Roseburia*, and *Porphyromonas*, *Fusobacterium*, and *Peptostreptococcus*, i.e., strains associated with periodontal disease (**Table [1](#T1){ref-type="table"}**) ([@B110]; [@B37]; [@B72]).

Moreover, fecal samples reflect the microbial colonization of tissues, as biopsies from adenomas and carcinomas have been similarly different from healthy mucosa ([@B37]). The findings that there is very little difference in microbiota composition between diseased and adjacent unaffected tissue suggest that the microbiome undergoes a systemic change, affecting the whole community ([@B75]; [@B37]). Such results support the driver/passenger model, the idea that certain strains disturb the microbial community and the mucosal microenvironment (drivers) and such changes lead to subsequent colonization by pathobionts and pathogens (passengers) ([@B122]). Both the drivers and the passengers modulate the local microenvironment through different means, such as virulence factors or metabolic activity. Drivers thus promote cancer initiation at the very beginning by their involvement in DNA damage, cell cycle regulation, apoptosis and epithelium proliferation, whereas passengers more likely promote tumorigenesis via chronic proinflammatory stimulation and direct tissue damage.

Drivers often include microbes that produce genotoxic substances, which damage DNA, or cyclomodulins, which can modulate the epithelial cell cycle -- recently thoroughly reviewed by [@B40] and [@B32]. *Bacteroides fragilis* and *Enterococcus faecalis* have the potential to damage epithelial cells and initiate cancer formation by producing the enterotoxin fragilysin and reactive oxygen species, such as superoxide, respectively ([@B54]; [@B126]). Several studies confirmed that *E. coli* strains encoding the genotoxic polyketide synthase (pks) island are associated with inflamed gut mucosa and CRC ([@B118]; [@B91]; [@B8]; [@B102]). Interestingly, members of the family Enterobacteriaceae, including *E. coli*, can produce several types of genotoxins or cyclomodulins. Cytotoxic necrotizing factors and cycle-inhibiting factor modulate the cell cycle and can lead to uncontrolled proliferation or cell cycle arrest, respectively ([@B119]; [@B85]). Cytolethal distending toxins, similarly to pks, induce DNA double-strand breaks and apoptosis, but can also promote proinflammatory cytokine production in the host ([@B14]). In summary, the interplay of these factors with gut epithelium and immune cells can promote low-grade inflammation and cancer initiation. Moreover, we can assume that these molecules represent just the tip of the iceberg of as yet unknown microbial products of gut commensals with the potential to harm the gut epithelium.

Mycobiome, i.e., the fungal microbiome, forms an integral part of the gut microbial community, although it is much less investigated then the bacterial part. The most common genera residing in a healthy gut are *Candida*, *Saccharomyces,* and *Cladosporium* ([@B50]). However, some non-commensal transient fungi, acquired with food or from the environment, can be also found in fecal samples and may comprise potentially pathogenic species. [@B127] have shown that the gut is colonized also by the oral mycobiome, as they found a genetically identical *Candida albicans* strain in the mouth and colon of patients with IBD. Unfortunately, data about fungal colonization of the digestive tract in relation to neoplastic diseases are still sparse. A disruption of the bacterial and fungal community -- dysbiosis, has been observed in individuals with IBD ([@B115]), who are known to be at increased risk of CRC development. Interestingly, reduced richness and diversity has been detected not only in bacterial, but also in fungal microbiome ([@B20]; [@B73]; [@B115]). For instance, the Cystofilobasidiaceae family, *Dioszegia* genus and *Candida glabrata* have been found to be enriched in Crohn's disease compared with healthy mucosa ([@B73]). The only published study on fungal microbiota in CRC deals with comparison of adenomas and adjacent tissues. [@B76] have observed an increased abundance of *Phoma* and *Candida* genera and *Candida tropicalis* in adenomas. As pathobionts, these genera may be involved in cancer initiation, but further studies are needed to investigate whether they work as drivers or passengers.

Microbiome in the colon makes use of various catabolic and anabolic pathways, which enable it to utilize a broad spectrum of substrates that are not absorbed in the small intestine. These pathways interact with the metabolism of xenobiotics and influence micronutrient bioavailability, lead to the production of essential vitamins and degradation of fibers, and regulate the secretion of various molecules ([@B7]). Different dietary components can shift the microbiome composition. For instance, a diet high in resistant starch increases the abundance of bacteria metabolizing non-digestible polysaccharides ([@B134]). Indeed, increased abundance of *Prevotella* and *Bacteroides* has been observed in individuals preferring high sugar and high protein diet, respectively ([@B137]). Our digestion pathways lack the enzymes for the degradation of resistant starch and dietary fiber but the distal gut microbiome encodes about 81 different families of glycoside hydrolases (bacterial polysaccharidases, glycosidases), which are not present in the human genome ([@B42]). The microbiome thus significantly contributes to the utilization of starch, primary fiber, host-derived secretions (mucus glycans), sucrose, and monosaccharides.

Subsequent fermentation of depolymerized molecules leads to the production of SCFAs, mainly acetate, propionate, and butyrate. Compared with other microbiomes in gene libraries, the human gut microbiome is enriched with genes involved in the pathways generating SCFAs ([@B42]). Main producers of butyrate within the human gut microbiome are *Faecalibacterium prausnitzii* and *Eubacterium rectale*/*Roseburia* group ([@B74]). SCFAs provide one of the most important sources of energy, not only for intestinal epithelial cells but also for muscles, kidneys, heart, and brain. Their physiologic production impacts the metabolism and transport through the epithelium, as well as epithelial cell renewal and differentiation. Moreover, SCFAs greatly influence the immune system, colonic functions, and carcinogenesis. Butyrate production, for example, improves gut barrier integrity and reduces local oxidative stress and inflammation ([@B77]). Recently, [@B61] came with an interesting finding that butyrate levels are much lower at the intestinal crypt base than in the lumen. Differentiated enterocytes use butyrate as an energy source and thus reduce its concentration along the way to the lamina propria, where a low concentration of butyrate keeps the epithelial progenitors proliferating and stimulates tolerogenic immune response ([@B61]). The role of SCFAs in cancerogenesis is not fully understood but their concentration could be an important factor.

On the other hand, degradation and fermentation of dietary proteins, peptides, and amino acids by bacteria generates by-products, such as phenols, indoles, ammonia, amines, and hydrogen sulfite, all of which are to some extent harmful to the host, being co-carcinogens, mutagens, and cellular toxins ([@B77]). Moreover, hydrogen released as the end-product of fermentation is processed by methanogenic species of Archaea (e.g., *Methanobrevibacter*) to methane, which changes local conditions (redox potential and pH) and thus regulates biochemical pathways ([@B42]).

Fungal metabolic activity includes the digestion of polysaccharides and fat residuals from the diet and host residuals, leading to the synthesis of a variety of secondary metabolites, which can substantially influence the surrounding prokaryotic and eukaryotic cells. An investigation of the relationship between fungal diversity and diet revealed a positive correlation of *Candida* with diet rich in saccharides and a negative correlation of *Aspergillus* with SCFAs ([@B50]). Thus, close relationships between bacterial and fungal metabolic requirements can help structure the microbial community in the gut. For instance, antimicrobial treatment can significantly disrupt the ecological balance of microbiota throughout the digestive tract. Antibiotics eradicate some sensitive bacteria and their niche can be subsequently invaded by other bacteria or fungi ([@B51]). Interestingly, a nested case-control study has shown that bacterial or fungal outgrowth after multiple penicillin treatments slightly increases the risk of CRC development ([@B15]). And, last but not least, consumption of food-associated mycotoxins -- secondary metabolites of fungi, has been linked to carcinogenesis throughout the digestive tract ([@B27]). Several *in vitro* studies have shown that exposure to mycotoxins affects apoptosis, intestinal barrier integrity and mucus production and causes DNA damage, suggesting a possible role of mycotoxins in CRC development; reviewed by [@B83].

Host--Microbiome Interaction and Disease Development
====================================================

Host derived proteoglycans, forming the mucus layer, are an important part of the mucosal immune system. They protect the epithelium from an extensive contact with the microbiome and reduce the risk of microbial invasion. The oral cavity and esophagus harbor several layers of tight and largely inert squamous epithelium, whereas the remaining parts of the digestive tract are covered with a single layer of intensely active cells ([@B58]). The structure of the mucus layers and types of mucin (MUC) vary widely along the digestive tract. The salivary glands in the oral cavity produce mainly MUC5B and MUC7, glands in the stomach and duodenum secrete gel-forming mucins MUC5AC and MUC6, and goblet cells in the gut specialize in MUC2 production ([@B63]; [@B135]; [@B90]). While in the small intestine, MUC2 forms a loose unattached mucus layer, in the colon it has two parts with different functions, an inner, attached layer and an outer, unattached one ([@B58]). The inner layer, which is about 50--100 μm thick, is dense and impenetrable to most microbes, while the outer layer flows with the gut content. Mucus contains distinct products of epithelial cells, such as antimicrobial peptides and secretory IgA, which play an important role in the protection of gut mucosa against pathogen invasion or excessive inflammatory response to commensals ([@B57]).

Interestingly, some members of the oral and gut microbiome can form a multilayer structure, composed of microbes and a polymeric matrix, termed a biofilm. Biofilm formation is one example of the mechanisms microorganisms use to evade antimicrobial defenses in the hostile environment of the host. Most biofilms are of polymicrobial nature and members of the biofilm community are distinct from the planktonic microbiota colonizing the mucosal surfaces throughout the body. Polymeric matrix formation and subsequent microbial colonization is the consequence of adhesion processes mediated by a wide spectrum of glycoproteins. Caries and periodontal disease are associated with biofilm formation by well-known periodontopathic bacteria. Biofilm in dental caries contains mainly streptococci, *L. acidophilus*, and *Actinomyces* and is secondarily colonized by anaerobic species, such as *F. nucleatum* and *P. gingivalis* ([@B21]). In periodontal disease, early biofilm colonizers are mainly represented by streptococci and *Actinomyces*. Later on, more pathogenic bacteria such as *F. nucleatum*, *P. gingivalis*, *T. forsythia*, *T. denticola*, and *A. actinomycetemcomitans* appear ([@B113]; [@B120]). The tendency of some microscopic fungi to form biofilms is also well-established in the literature. Recently, cooperation between *Candida* and oral commensal streptococci has been described as a significant factor in biofilm formation. Such cohabitation supports *Candida* growth and survival by providing it with an adhesive surface and the ability to invade tissue by promoting hyphae formation ([@B29]).

Current research has confirmed the presence of polymicrobial biofilms on gut mucosa of CRC patients, suggesting their possible role in CRC pathogenesis. Even in healthy mucosa, biofilm formation is associated with oncogenic potential and might be used to predict susceptibility to cancer development ([@B28]). These biofilms consist of periodontopathic bacteria -- *F. nucleatum* and *P. gingivalis*, as well as oral commensals, such as *Peptostreptococcus*, *Prevotella*, and *Parvimonas*, and their metabolic products, which may contribute to CRC progression ([@B71]). Microbial biofilms disrupt mucus layers, enabling potentially harmful microbes to attach to or even invade the mucosa and directly affect the epithelial cells by cytotoxic or genotoxic metabolites. Indeed, a recent study by [@B59] has provided evidence that the presence of biofilm increases polyamine metabolites in cancer tissues. Interestingly, fungal genera *Phoma* and *Candida* have been detected in higher quantities in adenoma biopsies ([@B76]). However, to date, the connection of these mixed-species biofilms with CRC has not been thoroughly studied.

When passing from the upper to the lower digestive tract, some previously mentioned bacteria change their oxygen requirements from facultative anaerobic to strict anaerobic, thereby switching to asaccharolytic and proteolytic metabolism ([@B33]). Microbial proteolytic enzymes break down the host's extracellular matrix and soluble factors to get nutrients and invade the tissue. Periodontopathic bacteria produce a wide spectrum of enzymes, including collagenases, elastases, peptidases, etc. For instance, gingipains are cysteine proteases secreted by *P. gingivalis*, classified as either arginine (Rgp) or lysine (Kgp) specific ([@B98]). They play a key role in biofilm formation, consequent host tissue destruction and vascular permeability induction ([@B60]; [@B33]). Some of the *P. gingivalis* proteases can degrade immunologically active molecules, such as immunoglobulins, cytokines and components of the complement, and thus modulate the antibacterial immune response. Similarly, oral streptococci produce proteases which have been shown to cleave IgA1 ([@B64]). Interestingly, 88% of the streptococci that initiate plaque formation on dental enamel possess IgA1 protease activity. Moreover, oral streptococci attack human immunoglobulin IgA1 not only by protease production but also by glycosidases (neuraminidase and beta-galactosidase). Oral streptococci thus cleave the alpha chains and also the carbohydrate moiety of IgA1. This finding suggests that the ability of streptococci to evade secretory immune mechanisms is one of the factors that enable them to colonize the oral cavity ([@B65]).

Another important feature of the microbiota that protects the host against pathogens is resistance to outsider invasion. Microbiota presents a competitive barrier to pathogenic microbes by active struggle for existence, fighting for nutrients and niche occupation. Moreover, commensals express antimicrobial effector molecules (bacteriocins) that serve as an effective tool for community shaping by endogenous microbiota. The third mechanism is indirect through constitutive stimulation of the mucosal immune system by commensal microbes, which strengthens the mucosal barrier, thus reducing pathogen translocation ([@B105]; [@B117]; [@B10]).

Mucosal surface of the gut is in continuous contact with foreign compounds derived from diet as well as from commensal or pathogenic microorganisms. Therefore, maintaining balance between the inner and outer milieu is the hallmark of the whole mucosal immune system. Many different cell types and their products are involved in this complex dialog, including epithelial and immune cells, cells of supporting tissues, antimicrobial peptides, growth factors, cytokines, and other mediators. Various components of microbiota can differentially trigger cellular pathways that shape local as well as systemic immune response and physiological functions. Recognition of these microbe-associated molecular patterns (MAMPs) is one of the most important features of the mucosal immune system. Receptors facilitating this are known as pattern-recognition receptors and can be divided into several families, such as retinoic acid inducible gene I-like receptors, nod-like receptors, toll-like receptors (TLR), and lectin receptors. Proinflammatory processes that are mediated by MAMPs, such as lipopolysaccharide, polysaccharides, peptidoglycan, flagella, and microbial DNA/RNA, activate pattern-recognition receptors on various host cells. These cells elicit local pro-inflammatory response and/or drive the differentiation of adaptive immune response ([@B107]; [@B129]). Therefore, a persistent inflammatory reaction of the host, constantly challenging the mucosal immune system, can lead to disease initiation ([@B123]). Appropriate immune response requires that recognition of commensals on the apical side of the epithelium induces tolerance, while recognition of pathogens on the basolateral membrane or inside the cell induces inflammation. Moreover, TLRs are important for stimulation of gut epithelium growth and barrier integrity as well as production of mucus, secretory IgA, antimicrobial peptides, and chemokines ([@B4]). Generally, the expression of *TLR*s in the epithelium is low in the steady state but increases during inflammation. Indeed, recent studies suggested the association of *TLR* polymorphisms with the progression of IBD into CRC, as *TLR*s expression is changed during gut inflammation ([@B11]).

Chronic inflammation leads to massive accumulation of activated immune cells and their mediators (cytokines and chemokines), residues of damaged cells, and large amounts of oxygen and nitrogen reactive species. Isolated dysplastic cells are further modified by the local microenvironment, as pro-inflammatory cells and cytokines promote the progression of dysplasia into carcinoma. During chronic inflammation, innate immune cells produce excessive quantities of reactive oxygen and nitrogen species that cause DNA and cellular damage. Pattern-recognition receptors signalization in the milieu of chronic inflammation activates MyD88-dependent pathways that promote pro-inflammatory cytokine release and subsequent tumor progression ([@B124]).

Conclusion
==========

There are two fundamental links between microbes and diseases. The first involves the host's recognition and immune response mechanisms and the second involves the microbiota itself, its presence and metabolic activity. Impaired barrier function, inadequate activation of the innate immune system and dysregulation of the appropriate mucosal immune response to gut microbiota (tolerance) are the primary elements of disease development. Low microbiome diversity seems to be a common feature in the pathogenesis of diseases of the digestive tract, suggesting that high microbial richness, both bacterial and fungal, is crucial for physiological homeostasis. Normally, a dynamic balance is maintained, where reduction of the bacterial community leads to outgrowth of the fungal one and vice versa. Disruption of this balance is associated with outgrowth of certain pathobionts at the expense of a complex community and may lead to disease initiation (**Figure [2](#F2){ref-type="fig"}**). Established dysbiosis is supported by local proinflammatory and tumor microenvironment which creates distinct nutritional conditions. A growing body of literature dealing with microbiome metabolic activities gradually unravels the complex host--microbe interactions. Nevertheless, collecting data about these interactions at the time of disease development is especially challenging in humans. In this respect, we still have to rely on retrospective clinical studies and animal models to generate helpful insights. Elucidation of the underlying mechanisms involving the interactions of the immune system with the microbiome, pathogens, or pathobionts can lead to the development of early screening and preventive interventions and, ultimately, reduce the risk of severe colon cancer.

![Oral microbiota moves to the gut and alter local microenvironment. In oral cavity, periodontal pathogens use several mechanisms, such as adhesion, biofilm formation and protease activity (see **Table [1](#T1){ref-type="table"}**), to disrupt the barrier and trigger the inflammatory changes in periodontium. In the gut, healthy stable microbiome can undergo temporary dynamic perturbations promoting growth of bacterial or fungal part of the microbiome **(A)**. These shifts are mostly reversible, do not disrupt mucosal barrier function, nor induce proinflammatory immune response. Nevertheless, microbes associated with periodontal disease can further disseminate into the gut becoming a part of altered gut microbiome with pathogenic potential. They can use similar mechanisms as in oral cavity and produce virulence and growth-promoting factors or substitute missing beneficial commensals. This can affect the stability of resident microbiome and promote their selective outgrowth leading to a dysbiosis **(B)**. Subsequent adhesion and biofilm formation, proteolytic activity or accumulation of harmful metabolites and soluble components can damage the integrity of gut barrier. These pathogenic mechanisms, together with dysregulated host immune response, can lead to inflammation and/or colorectal cancer initiation.](fmicb-09-00774-g002){#F2}
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